NNMTi can promote the differentiation of myoblasts in vitro and enhance the fusion and regeneration ability of muscle stem cells in aged mice.

30 µm NNMTi results in 18% MHC-positive myotube nuclei, representing a 45% increase in the extent of myoblast differential comparison to unmanaged differentiated mylatics (12% MHC-positive myoteube nuclei).

2 weeks (1 week pre-injury and 1 week post-injury)) has an effect on muscle regeneration after injury,

it results in 60% and 75% higher incidence of propagation/active muSCs at 5 mg/kg and 10 mg/kg, respectively.

The relative numbers of fibers with an EdU + myonucleus increased 40% and 48% with NNMTi treatment at 5 mg/kg and 10 mg/kg, respectively.

The odds ratio of fused myonuclei for control are 0.58 and 0.53 times the odds at the low and high NNMTi dose, respectively.

NNMTi (subcutaneous injection; 10 mg/kg; 1 week) produces no systemic toxicity in mice,

the levels of the glucose, cholesterol, plasma proteins, and electrolytes between control and NNMTi-treated samples show no difference in mice.

1-week post-injury daily repeat-dosing of NNMTi is well tolerated with no untoward systemic toxicity or behavioral implications in aged mice.